Your session is about to expire
Metformin vs Tradjenta
Introduction
For patients with type 2 diabetes, maintaining balanced blood sugar levels is crucial for managing symptoms and preventing complications. Metformin and Tradjenta are two such drugs that are commonly prescribed to control high blood sugar levels associated with this condition. They each influence different mechanisms in the body but both have a significant impact on lowering blood glucose concentrations to maintain a steady level.
Metformin works by suppressing liver glucose production while increasing insulin sensitivity in the muscle cells thus leading to decreased absorption of sugars from your diet. On the other hand, Tradjenta (linagliptin) belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors which work by increasing levels of incretin hormones like GLP-1 that help stimulate insulin release when required, especially after meals, thereby offering better glycemic control.
Metformin vs Tradjenta Side By Side
| Attribute | Glucophage | Tradjenta |
|---|---|---|
| Brand Name | Glucophage | Tradjenta |
| Contraindications | Severe kidney impairment, consumption of alcohol | Severe kidney impairment, consumption of alcohol |
| Cost | Around $35 for 60 tablets of 500 mg | Around $400 for 60 tablets of 5 mg |
| Generic Name | Metformin | Linagliptin |
| Most Serious Side Effect | Lactic acidosis | Signs of heart failure |
| Severe Drug Interactions | Insulin medications without proper doctor's advice | Insulin medications without proper doctor's advice |
| Typical Dose | 500–2550 mg/day | 5 mg/day |
What is Metformin?
Metformin, the generic name for Glucophage among other brand names, is a first-line medication in treating type 2 diabetes and was initially approved by the FDA in 1994. It works primarily by reducing glucose production and absorption, thus lowering blood sugar levels. Metformin also increases insulin sensitivity of your body's tissues, enhancing their ability to use glucose effectively. This drug is prescribed typically for managing blood sugar levels over time.
On the other hand, Linagliptin (the generic name for Tradjenta) belongs to a newer class of antidiabetic drugs known as DPP-4 inhibitors that were introduced in recent years with the first one getting approval from FDA in 2006. Tradjenta works differently than Metformin; it enhances body’s own ability to lower elevated blood sugar level mainly by inhibiting an enzyme called DPP-4 which leads to increased level of hormones that stimulate pancreas to produce more insulin and liver to produce less glucose.
While both medications are effective at maintaining control over long-term blood sugar levels, each has its unique side effects profile. Metformin might cause digestive problems like nausea or diarrhea while Tradjenta can result in symptoms such as sore throat or runny nose due its immune-modulatory actions.
What conditions is Metformin approved to treat?
Metformin and Tradjenta are both approved for the treatment of type 2 diabetes:
- Metformin is used as a first-line medication for the management of type 2 diabetes, particularly in overweight people or those with normal kidney function. It can also be used in combination with other drugs.
- Tradjenta (linagliptin) is a dipeptidyl peptidase-4 inhibitor that works by increasing levels of natural substances that lower blood sugar when it's high. It can be taken alone or alongside other medications such as metformin to manage blood glucose levels effectively.
How does Metformin help with these illnesses?
Metformin helps to manage type 2 diabetes by reducing the amount of glucose produced and released by the liver, and also helps muscles better absorb glucose from the bloodstream. It does this by activating an enzyme known as AMP-activated protein kinase (AMPK), which plays a crucial role in insulin signaling, whole body energy balance, and the metabolism of glucose and fats. Glucose is a simple sugar that provides energy to all of the cells in your body. However, too much circulating glucose can cause damage over time leading to complications such as heart disease or kidney disease commonly seen in diabetic patients. Therefore, Metformin's ability to lower blood sugar levels can limit these negative effects associated with high blood sugar levels in diabetes patients helping them manage their condition effectively.
What is Tradjenta?
Tradjenta is a brand name for linagliptin, which is a dipeptidyl peptidase-4 inhibitor (DPP-4i). DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme that destroys the hormone incretin. Incretins help the body produce more insulin when needed and reduce the amount of glucose being produced by the liver when it’s not needed. Linagliptin was first approved by the FDA in 2011. As Tradjenta does not directly affect insulin production or secretion like metformin, its side-effect profile differs from that of metformin; particularly in terms of causing less gastrointestinal complaints such as diarrhea and nausea (common side effects with metformin). The effectiveness on glucose control can be beneficial for type 2 diabetic patients who do not respond well to other oral antidiabetic drugs like metformin.
What conditions is Tradjenta approved to treat?
The Food and Drug Administration has given approval for Tradjenta to be used in the management of:
- Type 2 diabetes mellitus, as an adjunct to diet and exercise
- It can also be used alongside other medications when diet and exercise alone does not provide adequate control over blood sugar levels.
How does Tradjenta help with these illnesses?
Tradjenta is a medication that plays an essential role in the management of type 2 diabetes. It works by regulating the levels of insulin your body produces after eating. Like metformin, Tradjenta is used to improve blood sugar control in adults with type 2 diabetes mellitus. However, where Metformin works by reducing glucose production and absorption, therefore increasing insulin sensitivity, Tradjenta functions differently: it inhibits DPP-4 enzymes which slow down incretin hormones break down - resulting in increased insulin secretion and decreased glucagon production when glucose levels are high or normal (not during hypoglycemia). These actions collectively help to regulate and maintain healthy blood sugar levels throughout the day. Therefore, Tradjenta might be a preferred choice for patients who experience side effects from Metformin or need additional blood sugar control.
How effective are both Metformin and Tradjenta?
Both metformin and linagliptin (Tradjenta) are effective medications used in the management of type 2 diabetes, with metformin being approved by the FDA more than a decade before linagliptin. Metformin works primarily by decreasing hepatic glucose production and increasing insulin sensitivity, while linagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades incretin hormones leading to increased insulin release.
The efficacy of both drugs in managing blood sugar levels was directly studied in multiple clinical trials. A 2015 study showed that combined therapy using both metformin and linagliptin improved glycemic control without causing weight gain or increasing hypoglycemia risk compared to monotherapy. In fact, none of the metrics used to measure their effectiveness at controlling blood glucose levels significantly differed between patients receiving metformin alone and those receiving both drugs.
A review published in 2017 highlighted that metformin is commonly used as first-line treatment for type 2 diabetes due its well-established safety profile, absence of weight gain or hypoglycemia when used alone, reduced cardiovascular morbidity and mortality data along with its cost-effectiveness. Its dose ranges from 500 mg/day up to a maximum dose of about 2000 mg/day depending on patient tolerance and response.
Also in recent years, numerous meta-analyses have shown that DPP-4 inhibitors like Tradjenta can be effectively added to existing antidiabetic regimens if additional glycemic control is needed without significant adverse effects including hypoglycemia or weight gain which are common concerns with other classes of oral antidiabetics. Linagliptine has also been shown not require any dosage adjustment for renal impairment unlike many others in this class making it suitable choice for chronic kidney disease patients.
Related trials for metformin and tradjenta
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Metformin typically prescribed?
Oral dosages of Metformin range from 500–2550 mg/day, but studies have indicated that an initial dose of 500 mg/day is usually sufficient for controlling blood glucose levels in adults with type 2 diabetes. Dosage can be increased gradually to a maximum of 2550 mg/day if there is no adequate response. On the other hand, Tradjenta (linagliptin) has a simpler dosage regime - it's typically taken as one 5mg tablet once daily, and this does not usually need to be adjusted based on the patient's response. Regardless of which medication you're using, your doctor should closely monitor your condition and adjust your dosage accordingly.
At what dose is Tradjenta typically prescribed?
Tradjenta treatment for type 2 diabetes is typically initiated at a dosage of 5 mg/day, taken once daily. There's no need for dose adjustments as it can be taken with or without food. The convenient dosing schedule means the same amount can be administered regardless of fluctuating blood sugar levels. However, if there is insufficient response to treatment after several weeks, consult your healthcare provider as they may consider testing an alternative therapy or combination treatment with Tradjenta and other anti-diabetic drugs to achieve glycemic control. Please remember that every individual’s reaction to medication varies; always follow your doctor's instructions regarding dosage and frequency.
What are the most common side effects for Metformin?
Common side effects of Metformin can include:
- Diarrhea, nausea, and upset stomach
- Vomiting
- Loss of appetite or anorexia
- Tiredness or general weakness (asthenia)
- Gas (flatulence)
- Heartburn or acid reflux
- Metallic taste in the mouth
On the other hand, Tradjenta may cause these common side effects:
- Nasopharyngitis (cold symptoms such as sore throat, runny nose)
- Upper respiratory tract infection
- Urinary tract infection
- Rash or skin reactions
Remember to consult with your healthcare provider if you are experiencing any adverse events.
Are there any potential serious side effects for Metformin?
While both Metformin and Tradjenta are utilized to manage blood sugar levels in people with type 2 diabetes, they can have different side effects:
- Hypoglycemia or low blood sugar: Symptoms may include headache, hunger, sweating, irritability, dizziness, nausea, fast heart rate.
- Signs of an allergic reaction such as hives; difficulty breathing; swelling of your face, lips, tongue or throat
- Lactic acidosis (a build-up of lactic acid in the body) characterized by unusual muscle pain or weakness; trouble breathing; stomach pain or vomiting; dizziness upon standing
- Pancreatitis - severe upper stomach pain spreading to your back accompanied by nausea and vomiting
- Joint Pain
- Skin reactions like blistering and peeling skin rash
It is important that if you experience any of these symptoms while taking Metformin or Tradjenta to seek immediate medical attention. It's also crucial to discuss all possible side effects with your healthcare provider before starting on either medication.
What are the most common side effects for Tradjenta?
When comparing Metformin to Tradjenta, Tradjenta may cause a range of side effects such as:
- Runny or stuffy nose
- Sore throat and coughing
- Headache
- Nausea and stomach discomfort
- Diarrhea
- Hypoglycemia (low blood sugar) when used with other diabetes medications
- Joint pain or stiffness.
It's worth noting that although these side effects are possible, they do not occur in everyone who takes the medication, as each individual's body responds differently.
Are there any potential serious side effects for Tradjenta?
While Tradjenta is generally well-tolerated, there are instances where it can cause severe side effects. These might include:
- Signs of a serious allergic reaction: skin rash or hives, itching, swelling in your face or throat, difficulty breathing, severe dizziness.
- Symptoms of heart failure such as shortness of breath at rest or with exertion; unusual tiredness; sudden unexplained weight gain; and swelling in the ankles, feet or hands.
- Unusual muscle pain that doesn't go away
- Extreme fatigue
- Unexplained nausea or vomiting
- Stomach pains
- Dizziness and/or lightheadedness If you experience any of these symptoms while taking Tradjenta, seek immediate medical attention.
Contraindications for Metformin and Tradjenta?
Both Metformin and Tradjenta, as well as other drugs for managing diabetes, may cause side effects in some individuals. If you notice symptoms of lactic acidosis such as unusual tiredness or weakness, trouble breathing, stomach pain with nausea or vomiting, irregular heartbeat or feeling cold (especially hands and feet), you must seek immediate medical attention.
Neither Metformin nor Tradjenta can be taken if you are taking insulin medications without proper doctor's advice. Always inform your healthcare provider about any medication including over-the-counter drugs and supplements that you're currently taking; this is crucial to prevent dangerous interactions with either Metformin or Tradjenta.
People who have severe kidney impairment should abstain from using these medications due to the potential risk of lactic acidosis. Moreover, avoid consumption of alcohol while on these treatments since it may increase the risk even further.
How much do Metformin and Tradjenta cost?
For the brand name versions of these drugs:
- The price of 60 tablets of Tradjenta (5 mg) averages around $400, which works out to approximately $13 per day.
- The price for 60 tablets of Metformin (500 mg) is significantly less expensive, averaging around $35, working out to approximately $0.58 per day.
Thus, if you are considering cost as a factor in your decision-making process, Metformin is substantially cheaper than Tradjenta on a per-day treatment basis. However, it's essential to understand that cost should not be the primary determinant when choosing between these medications.
As for their generic equivalents:
- Linagliptin (the active ingredient in Tradjenta), unfortunately isn't available as a generic version currently.
- Generic metformin is even more affordable with prices ranging from about $.01 to $.02 per tablet depending on where you purchase them and whether you buy in bulk or not. This makes the daily cost very low indeed - typically only pennies per day at most common dosages (1000 – 2000 mg/day).
Popularity of Metformin and Tradjenta
Metformin, both in its generic form and under brand names such as Glucophage, was estimated to have been prescribed to about 83.6 million people in the US in 2020. Metformin accounted for nearly a third of all prescriptions for type 2 diabetes medications in the US that year. As a first-line treatment for type 2 diabetes, metformin has maintained steady prevalence since it was introduced.
Linagliptin, including the brand version Tradjenta, was prescribed to approximately 1.7 million people in the USA during the same period. In terms of prescriptions within antidiabetic drugs class Dipeptidyl peptidase-4 (DPP-4) inhibitors which linagliptin is part of, it accounts for around 12% with Tradjenta's popularity slowly growing since being approved by FDA in May 2011.
Conclusion
Metformin and Tradjenta (linagliptin) are both widely used for the management of type 2 diabetes, with numerous clinical studies indicating their effectiveness in controlling blood glucose levels. They can be used together if a single agent is not adequate to control blood sugar levels, although this should always be under the careful consideration of a healthcare provider due to potential drug interactions.
Their mechanisms of action differ significantly; metformin reduces glucose production in the liver and increases insulin sensitivity, while Tradjenta works by increasing hormones that stimulate insulin secretion from the pancreas and decreasing glucagon which leads to lower hepatic glucose production.
Metformin is considered a first-line treatment option in type 2 diabetes due to its proven safety record over many decades, efficacy, weight neutrality and cost-effectiveness. In contrast, Tradjenta would typically be added on as an adjuvant therapy if metformin alone isn't enough or for patients who cannot tolerate metformin's gastrointestinal side effects.
Both drugs come in generic versions offering significant cost savings. Metformin usually requires an adjustment period where dosages are gradually increased until optimal glycemic control is achieved without causing side effects like diarrhea or nausea.
Side effect profiles between these two drugs are quite different though generally mild; metformin may cause digestive issues whereas Tradjenta has been associated with upper respiratory tract infections and headache. For both medications, it's crucial that patients closely monitor their blood sugar levels when starting treatment or changing doses.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Ashraf, S., Upreti, P., Karki, S., Khan, M., & Nasr, R. (2022, April 17). Metformin-Associated Lactic Acidosis: A Case Report and Review. Cureus. Springer Science and Business Media LLC.http://doi.org/10.7759/cureus.24220
- McKeage, K. (2014, October). Linagliptin: An Update of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-014-0308-3
- Gignilliat, J. (1996, October). Re: TDE article, Pharmacy Update, "Metformin: A Biquanide". The Diabetes Educator. SAGE Publications.http://doi.org/10.1177/014572179602200502
- Zheng, J., Woo, S.-L., Hu, X., Botchlett, R., Chen, L., Huo, Y., & Wu, C. (2015, February 12). Metformin and metabolic diseases: a focus on hepatic aspects. Frontiers of Medicine. Springer Science and Business Media LLC.http://doi.org/10.1007/s11684-015-0384-0
- Bajaj, M., Gilman, R., Patel, S., Kempthorne‐Rawson, J., Lewis‐D'Agostino, D., & Woerle, H. ‐J. (2014, July 7). Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24‐week randomized, double‐blind study. Diabetic Medicine. Wiley.http://doi.org/10.1111/dme.12495
- Blonde, L., Dailey, G. E., Jabbour, S. A., Reasner, C. A., & Mills, D. J. (2004, March 5). Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion. Informa Healthcare.http://doi.org/10.1185/030079904125003278
- Dunn, C. J., & Peters, D. H. (1995, May). Metformin. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-199549050-00007
- Le, S., & Lee, G. C. (2019, May 23). Emerging Trends in Metformin Prescribing in the United States from 2000 to 2015. Clinical Drug Investigation. Springer Science and Business Media LLC.http://doi.org/10.1007/s40261-019-00799-0